Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
- Conditions
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00958256
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2019-09-18
- Target Recruit Count
- 124
- Registration Number
- NCT00948922
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT00937495
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 206
- Registration Number
- NCT00931918
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸Georgia Cancer Specialists, Atlanta, Georgia, United States
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT00923247
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 40
- Registration Number
- NCT00920855
- Locations
- 🇺🇸
Family Cancer Center, PLLC, Collierville, Tennessee, United States
🇺🇸Pacific Oncololgy & Hematology, Encinitas, California, United States
🇺🇸James R. Berenson, M.D., Inc., West Hollywood, California, United States
A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Sirtris, a GSK Company
- Target Recruit Count
- 24
- Registration Number
- NCT00920556
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Desensitization in Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 44
- Registration Number
- NCT00908583
- Locations
- 🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
- Conditions
- Interventions
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 163
- Registration Number
- NCT00908232
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-05-19
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 58
- Registration Number
- NCT00903968
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Cape Cod Hospital, Hyannis, Massachusetts, United States
🇺🇸Newton-Wellesley Hospital, Newton, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.